


Glenmark gets FDA nod for Voriconazole Tablets

04 September 2015 | News | By BioSpectrum Bureau

Glenmark gets FDA nod for Voriconazole Tablets



Glenmark Pharmaceuticals (Glenmark) has been granted final approval by the United States Food and Drug Administration (US FDA) for Voriconazole Tablets, 50 mg and 200mg, the therapeutic equivalent of Vfend Tablets, 50 mg and 200 mg of PF Prism C.V. (Prism).

According to IMS Health sales data for the 12 month period ending July 2015, the Vfend market¹ achieved annual sales of approximately \$91.4 million.

Voriconazole is used in certain types of fungal infections.